Status:
COMPLETED
Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment
Lead Sponsor:
Calo Psychiatric Center
Conditions:
Schizophrenics
Eligibility:
All Genders
30-69 years
Phase:
PHASE1
PHASE2
Brief Summary
Schizophrenia is a chronic and severe psychiatric disorder, these patients suffer from positive symptoms, negative symptoms and cognitive deficits, of which working memory problems are considered a ce...
Detailed Description
This is a two and half-one years, single-arm, nonrandomized, open-label study which was conducted between Jan 2015 to Jun 2017 including from a psychiatric center in southern Taiwan. The stable schizo...
Eligibility Criteria
Inclusion
- All of them had to meet the diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
Exclusion
- Patients who had comorbid serious medical illnesses, and may therefore present substantial clinical risk due to pharmacotherapy, were excluded from the sample, as were pregnant and lactating women.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04754750
Start Date
January 1 2015
End Date
June 1 2017
Last Update
February 15 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.